Background-Molecular imaging is a fast emerging technology allowing noninvasive detection of vascular pathologies.
A therosclerosis is a progressive disease driven by the adherence of activated platelets and monocytes to the site of vascular inflammation and the accumulation of lipids and lipid-loaded macrophages in the artery wall. [1] [2] [3] Atherosclerosis is often silent for decades until it becomes clinically evident. 3 Even though chronic atherosclerotic lesions can significantly reduce blood flow, most acute cases of myocardial infarction and stroke are caused by atherothrombosis, triggered by the exposure of thrombogenic material at sites of plaque ruptures, inducing the activation of the coagulation cascade and platelet adhesion, activation, and aggregation. 4 -7 This finally leads to thrombus formation and vessel occlusion.
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Rapid and reliable detection of thrombosis is a highly attractive aim in medical imaging with potential major benefits for patients. One promising strategy is the development of targeted molecular imaging probes. The glycoprotein (GP) IIb/IIIa complex, also known as integrin ␣IIb␤3 (CD41/ CD61), is the main receptor mediating platelet aggregation and the most abundant receptor expressed on the platelet surface. 8, 9 GP IIb/IIIa undergoes a conformational change from a low-to a high-affinity state on platelet activation. This allows fibrinogen binding, platelet aggregation, and thrombus formation. 8, 9 These features make GP IIb/IIIa an ideal target for molecular imaging of thrombosis. We have developed conformation-specific anti-GP IIb/IIIa single-chain antibodies (scFvs), 9 -11 some of which bind specifically to a LigandInduced Binding Site (LIBS) on activated GP IIb/IIIa, 9 -11 and have previously demonstrated the ability of scFv anti-LIBS to detect activated platelets in magnetic resonance imaging in the context of inflammation and thrombosis. [12] [13] [14] [15] Ultrasound imaging has several advantages over other imaging modalities. It is noninvasive, is inherently real time, is free of radiation-associated risk, has no known side effects, and only rarely causes discomfort in patients. Furthermore, the equipment is generally less expensive than, for example, magnetic resonance imaging equipment, is highly portable, and is already present in most hospitals.
Here, we present a noninvasive approach for the specific detection of activated platelets, platelet aggregates, and thrombi that could be used for early and sensitive detection of thrombi and for monitoring of the success or failure of thrombolysis. By conjugating scFv anti-LIBS to microbubbles (LIBS-MBs), we demonstrate that targeted molecular imaging of LIBSMBs with contrast-enhanced ultrasound is well suited to detect and visualize thrombi in vivo in the carotid artery of mice. Pharmacological thrombolysis was performed to further demonstrate that LIBS-MB imaging and molecular ultrasound imaging are able to reliably detect a reduction in thrombus size. Overall, the presented targeted molecular imaging approach has potential to be translated to clinical application in humans after further extensive experimental testing.
Methods
A detailed description of the methods is provided in the online-only Data Supplement.
Generation, Expression, and Purification of scFvs
The generation of the 2 different scFvs (activated GP IIb/IIIa-targeted scFv anti-LIBS and nontargeted mut-scFv) has been described previously. 9, 10, [12] [13] [14] [15] Briefly, both scFvs were subcloned into the AviTag containing pAC6 vector system, transformed into electrocompetent EVB101 (all Avidity, Aurora, CO). In vivo biotinylation was performed according to the manufacturer's instruction. All scFvs carry a 6X-His tag, which was used for purification with nickel-based metal affinity chromatography (Invitrogen, Carlsbad, CA).
Evaluation of the Purity and Efficiency of In Vivo Biotinylation of scFv-AviTag Constructs
The purity of the proteins was analyzed with SDS-PAGE, and the efficiency of in vivo biotinylation was determined by Western blot. An anti-6X His-tag antibody horseradish peroxidase was used to detect the protein construct, and streptavidin horseradish peroxidase (BD Bioscience, Franklin Lakes, NJ) was used to determine the success of in vivo biotinylation.
Flow Cytometry
Platelet-rich plasma was obtained by centrifugation of blood collected from healthy volunteers. Diluted platelet-rich plasma was either not activated or activated with ADP before incubation with purified scFv, followed by incubation with an anti-Penta-His Alexa Fluor 488 -conjugated monoclonal antibody (Qiagen, Hilden, Germany) or R-phycoerythrin streptavidin (Jackson ImmunoResearch, US). Samples were fixed and analyzed by FACS Calibur (BD Bioscience, Franklin Lakes, NJ).
Conjugation and Purification of Biotinylated scFv-AviTag Constructs to Streptavidin-Coated MBs
Conjugation of 200 g scFv-AviTag to 1.5ϫ10 9 /mL Targestar-SA MBs (Targeson, Inc, San Diego, CA) was performed at room temperature for 20 minutes. This reflects an excess of scFv aiming for saturation of all streptavidin binding sites on the MBs. To remove unbound scFv, purification of conjugated MBs was performed with a gradient centrifugation. MBs were incubated with anti-Penta-His Alexa Fluor 488 -conjugated monoclonal antibody or R-phycoerythrin biotin (Sigma, Munich, Germany) and analyzed by FACS Calibur.
Inverted Flow Chamber Adhesion Assay
Inverted flow chamber in vitro adhesion assays were performed with a glass capillary that was coated with either washed, ADP-activated platelets or 100 g/mL collagen. To accommodate the buoyancy of the MBs, the capillary was used in an inverted manner. A syringe pump (PhD 2000; Harvard Apparatus, Holliston, MA) was used in the aspiration mode to withdraw the MB dispersion through the flow chamber at defined shear rates.
In Vivo Mouse Experiments
Animals were injected with either noncoupled MBs or those coupled to scFv anti-LIBS (LIBS-MBs) or mut-scFv alone (control MBs) after ferric chloride-induced carotid artery injury. All experiments involving animals were approved by the Alfred Medical Research and Education Precinet Animal Ethics Committee (E/0910/2010/E).
Animals were anesthetized with ketamine (50 mg/kg; Parnell Laboratories, New South Wales, Australia) and xylazine (10 mg/kg; Troy Laboratories, New South Wales, Australia) and placed on a 37°C heater mat to prevent hypothermia.
Femoral Vein Catheterization and Ferric Chloride Injury to the Carotid Arteries of Mice
A catheter was placed in the femoral vein to facilitate injection. The left common carotid artery was dissected from circumferential connective tissues, and a small filter paper saturated with 6% ferric chloride was placed under the carotid artery of the animal for 3 minutes to induce injury, which results in the formation of a nonocclusive thrombus. The presence of nonocclusive thrombi was previously confirmed by histology. 15 
In Vivo Ultrasound Molecular Imaging of Carotid Artery Thrombosis and Thrombolysis
Ultrasound of animals was performed with a Vevo770 high-resolution imaging system (VisualSonics Inc., Toronto, Canada) using a 40-MHz RMV704 transducer. Animals were placed on the VisualSonics imaging station after ferric chloride injury was performed to the left carotid artery. Videos and images were acquired before, during, and at several time points after injection of 1.5ϫ10 7 MBs in 100 L, as counted in a Neubauer hemocytometer. Videos and images were analyzed with linear contrast agent imaging software (VisualSonics Inc) or Image Pro Plus. Frames obtained before the injection of MBs were digitally subtracted from the frames obtained 20 minutes after injection.
To monitor thrombolysis, we injected 500 IU/g urokinase plasminogen activator (UPA) (Medac, Wedel, Germany). Repetitive ultrasound imaging sequences were performed. The animals in the vehicle group were treated with saline. In addition, a second bolus of LIBS-MBs was administrated 30 minutes after treatment with UPA.
Conversion of the Gray-Scale Area Intensity Value to Decibels
The Vevo770 ultrasound scanner uses a linear contrast mode. To convert gray-scale values to decibel values, a tissue phantom (12% gelatin and 6% Metamucil) was imaged to obtain gray-scale values at 2-dB intervals from 10 to 30 dB. System decibel and associated gray-scale values were plotted on an x-y graph to obtain a linear formula that enables a conversion from gray-scale data points to decibel values ( Figure 
Statistical Analysis
Unless otherwise specified, data are expressed as meanϮSEM. Flow cytometry, flow chamber, and data for thrombolysis were analyzed with 2-way repeated measures ANOVA with a Bonferroni multiplecomparison post test. Decibel values for thrombi imaging were analyzed by use of a 1-way ANOVA with Bonferroni correction for multiple testing. Differences were considered significant at PϽ0.05. To determine interobserver reproducibility, the ultrasound images were analyzed by 5 separate investigators using Image-Pro Plus 6.0 software for the determination of gray-scale area intensity units. For determination of intraobserver reproducibility, the ultrasound images were analyzed 3 times. The differences obtained before and after the injection of the respective MBs were analyzed using the intraclass correlation coefficient analysis. All analyses containing Ͼ2 groups were corrected by post hoc analysis, and the corrected P values are given. Statistical analyses were performed with GraphPad Prism 5.0.
Results

Cloning, In Vivo Biotinylation, and Purification of scFv-AviTag Constructs
The generation of scFv antibodies suitable for MB conjugation was achieved by adding a C-terminal AviTag, an avidin tag that enables the scFv to bind biotin. The success of DNA amplification and restriction digest was evaluated by electrophoresis ( Figure 1A ). Both constructs were visualized at the 1-kB mark after amplification with polymerase reaction product and restriction digest. The pAC6 plasmid was visualized at the 3-kB mark after restriction digest. After the respective constructs were cloned into the pAC6 plasmid, transformed, and purified, they were analyzed by gel electrophoresis. After production of the scFvs, SDS-PAGE and Western blot were used to prove successful purification and in vivo biotinylation of the recombinant protein ( Figure 1B) .
Evaluation of the Functionality of the scFv-AviTag Constructs by Flow Cytometry
To confirm retained binding capacity of the scFv to activated platelets, the functionality of the scFv-AviTag constructs was evaluated with anti-Penta-His Alexa Fluor 488-conjugate ( Figure 2A ). No binding was observed for the isotype control to activated or nonactivated platelets (1.69Ϯ0.2 versus 1.47Ϯ0.07 arbitrary units [AU], respectively; meanϮSD; Pϭ0.88) or for the control mut-scFv construct (1.48Ϯ0.02 versus 1.5Ϯ0.09 AU; Pϭ0.99). Incubation of activated platelets with the scFv anti-LIBS construct resulted in an increase in fluorescence intensity compared with nonactivated platelets (24.96Ϯ3.47 versus 2.69Ϯ0.16 AU; PϽ0.001). Similar results were obtained when the efficiency of in vivo biotinylation and scFv functionality were determined with R-phycoerythrin streptavidin on flow cytometry ( Figure 2B ). The specificity of scFv anti-LIBS targeting activated platelets was demonstrated in a whole-blood flow cytometry assay using dual staining with CD41-phycoerythrin for platelet 
Attachment of Targeted MBs to Activated Platelets and Microthrombi In Vitro
Conjugation of scFv to MBs was demonstrated in flow cytometry ( Figure 3A) . Conjugated MBs showed a decrease in fluorescence intensity as observed with R-phycoerythrin biotin (PϽ0.01) and an increase with Alexa Fluor 488 -coupled anti-Penta-His antibody (PϽ0.01). Binding performance in vitro was investigated by flow chamber experiments (Figure 4 ). After 5 minutes of continuous low shear rate (50 seconds Ϫ1 ) over activated platelets, the attachment of LIBS-MBs was significantly greater compared with either MBs or control MBs (84Ϯ10 versus 15Ϯ2 versus 13Ϯ2 MBs, respectively; adherent MBs, PϽ0.001; Movies I-III in the onlineonly Data Supplement). Competitive inhibition assays via preincubation of activated platelet monolayers with 1.5 mg/mL scFv anti-LIBS demonstrated a significant reduction of LIBS-MB attachment (PϽ0.001) to the background level, as seen with control MBs and MBs. After the initial 5 minutes, the shear rate was increased to 1000 seconds Ϫ1 . With the increase in shear rate, LIBS-MBs remained firmly attached to the activated platelet coating, whereas both control MBs and MBs alone dislodged (81Ϯ12 versus 8Ϯ1 versus 8Ϯ1 MBs, respectively; PϽ0.001). The shear rate was further increased to 6000 seconds Ϫ1 , and LIBS-MBs continued to be firmly bound to the coated activated platelets, whereas the majority of control MBs and MBs were dislodged (74Ϯ5 versus 2Ϯ1 versus 3Ϯ1 MBs, respectively; PϽ0.001), demonstrating Similar results were obtained for flow chamber experiments with microthrombi ( Figure 5 ) in which attachment of LIBS-MBs at 50 seconds Ϫ1 was significantly higher compared with that of control MBs and MBs (34Ϯ3 versus 7Ϯ1 versus 11Ϯ1 MBs, respectively; PϽ0.01). When shear rates were increased to 1000 and 6000 seconds Ϫ1 , LIBS-MBs were attached more firmly than control MBs and MBs (27Ϯ1 versus 3Ϯ1 versus 6Ϯ1 MBs and 16Ϯ1 versus 0Ϯ0 versus 1Ϯ0 MBs, respectively; PϽ0.01). In addition, experiments performed directly at 1500 seconds Ϫ1 led to adhesion of LIBS-MBs (66Ϯ2 MBs per 2 cm of the flow chamber capillary) to microthrombi, whereas no adhesion at all was noted in control MBs or MBs. Moreover, LIBS-MB attachment could be localized specifically to activated platelets in microthrombi ( Figure 5 ). Direct dual fluorescence staining of LIBS-MBs attached to activated platelets in a flow chamber experiment showed fluorescence-labeled double staining of activated platelets and LIBS-MBs ( Figure 3B ).
In Vivo Molecular Imaging of Thrombus Formation
Imaging of the mouse carotid artery on ultrasound typically shows luminal blood as black or a dark color and MBs as a bright white color in the lumen ( Figure 6A ). Eight mice were injected with MBs, 10 mice with LIBS-MBs, and 8 mice with control MBs. The decibel values of the thrombi on the carotid artery before injection of MBs were analyzed as baseline. A certain amount of background was observed with recirculating MBs. Because this blood pool background has clearly returned to baseline levels at 20 minutes ( Figure IV in the online-only Data Supplement), we chose this time point for analysis. On real-time ultrasound imaging, the thrombus visualized after injection with LIBS-MBs as a white and bright signal, whereas the thrombus visualized after injection of control MBs or MBs was dull ( Figure 6B and Movies IV-VI in the online-only Data Supplement). Figure 6C shows the calculated differences in decibels 20 minutes after MB injection compared with the preinjection baseline. For the LIBS-MBs, a significant increase in decibels occurred compared with MBs or control MBs (9.55Ϯ1.7 versus 2.0Ϯ1.4 versus 1.46Ϯ1.3 dB, respectively; PϽ0.01). Although thrombus identification and quantification with these B-mode images provide the necessary scientific and clinical information, digital subtraction and color highlighting were used for demonstrational purposes and as an aid to facilitate immediate recognition of thrombi. Frames obtained before MB injection were subtracted from those obtained after MB injection. Areas brighter than the reference image are presented in green after analysis with digital subtraction ( Figure  6D and Movies IV-VI in the online-only Data Supplement). Movement artifacts can be discriminated by their localization . The number of MBs was counted after 5 minutes of continuous flow. Attachment of LIBS-MBs was significantly higher than for control MBs or MBs. After an initial 5 minutes of continuous flow, the shear rate was increased to 1000 seconds Ϫ1 . LIBS-MBs remained firmly attached to the activated platelet coating, whereas control MBs and MBs were dislodged. Similar results were obtained when the shear rate was increased to 6000 seconds Ϫ1 . MeanϮSEM values for 3 independent experiments are given (**PϽ0.01, ***PϽ0.001). B, Representative microscopy images of flow chamber adhesion assays demonstrating that more LIBS-MBs attached to the microthrombi on collagen coating of capillaries compared with MBs and control MBs. C, Representative microscopy images of PAC-1-FITC staining for platelets, demonstrating that LIBS-MBs attached specifically to activated platelets in microthrombi. These assays were analyzed with a 2-way repeated measures ANOVA with the Bonferroni post test.
outside the vessel lumen. Statistical analyses for interobserver and intraobserver reproducibility were analyzed with the intraclass correlation coefficient analysis between the 5 different investigators or the 3 independent analyses by an individual observer. The obtained intraclass correlation coefficients were 0.984 and 0.993, respectively, demonstrating specific and reproducible antibody-targeted ultrasound imaging in vivo.
In Vivo Molecular Imaging of Thrombolysis
Pharmacological thrombolysis was used to further determine whether molecular ultrasound imaging with LIBS-MBs is able to monitor the thrombus size, particularly any reduction in size. After the administration of UPA, a reduction in thrombus size and/or thrombus dislodgement could be directly observed (Figure 7 and Movies VII-X in the onlineonly Data Supplement). The baseline area before injection of UPA was set to 100%, and the area was calculated every 5 minutes for 60 minutes (Figure 7 ). There were no significant changes in thrombus size in the vehicle group over 60 minutes, whereas thrombus size was significantly reduced in the UPA-treated group (PϽ0.001; nϭ3 each). Similar trends of results were obtained in comparisons of the thrombus area reduction to thrombus area gray-scale intensity unit reduction ( Figure 7B and 7C) . Histology of carotid artery thrombi of vehicle-or UPA-treated mice confirmed the differences in thrombus size between the 2 groups ( Figure VA and VB in the online-only Data Supplement). Finally, we imaged thrombi and thrombolysis without MBs ( Figure VC and VD in the online-only Data Supplement) to demonstrate the lack of visual distinction of thrombi in conventional ultrasound without the LIBS-MB molecular imaging approach.
To investigate whether a second dose of MBs was required to successfully monitor the stages of thrombolysis, we performed 2 experiments comparing the time span between the first dose injection of MBs and UPA administration ( Figure  VI in the online-only Data Supplement). No significant changes in decibels were observed after a second dose of LIBS-MBs when LIBS-MBs were recirculating and thus available during thrombolysis (Pϭ0.56). However, if UPA treatment was administrated Ͼ30 minutes after LIBS-MB injection, a significant decrease in gray-scale intensity unit could be seen (PϽ0.01). This value was subsequently increased when a second dose of LIBS-MBs was administrated (PϽ0.05).
In addition to longitudinal section imaging, cross-sectional ultrasound imaging was performed. The results in monitoring thrombolysis of cross-sectional analysis are similar in overall outcome to those of the longitudinal section analysis (nϭ4; Pϭ0.36; Figure VII in the online-only Data Supplement). However, because of the limited examinable area in the cross section of the mouse carotid artery (diameter, 0.3 mm) and the technical challenges that accompany this approach, this variability limits accuracy of cross-sectional imaging in mice.
Discussion
Direct ultrasound imaging of thrombi is a long-sought-after technical achievement that could be broadly used in various clinical settings and would provide major benefits for patients. This study shows that scFvs, which are specific for the activated GP IIb/IIIa receptor on platelets, can be conjugated to MBs and can be successfully used for selective in vivo ultrasound imaging of thrombi. To the best of our knowledge, this is the first demonstration of ultrasound imaging visualizing the attachment of scFv-targeted MBs to a thrombus in vivo. These data raise the possibility of a noninvasive and inexpensive tool to accurately diagnose the early stages of thrombus formation and to monitor the success or failure of pharmacological thrombolysis.
Ultrasound has evolved from a crude anatomic imaging to a high-resolution and 3-dimensional imaging tool. The recent technique of molecular ultrasound imaging promises to provide a platform for functional characterization of diseased tissue without the need for invasive biopsies or other surgical procedures. 16 -18 Currently, clinical molecular imaging is focusing mainly on magnetic resonance imaging or positron emission tomography/single photon emission computed tomography as an imaging modality. However, molecular imaging with ultrasound will offer a real-time, inexpensive, Ultrasound images were obtained every 5 minutes, and thrombus size was calculated. The thrombus size of the vehicle group stayed constant, whereas those administrated with UPA fluctuated over 60 minutes of monitoring. B, Baseline areas before the injection of UPA and vehicle were set to 100%, and areas were calculated every 5 minutes for 60 minutes. Thrombus sizes were traced and calculated with VisualSonics software. C, Baseline areas before the injection of UPA and vehicle were set to 100%, and gray-scale intensity units were calculated every 5 minutes for 60 minutes. Gray-scale intensity units were analyzed with Image Pro Plus. The area of interest for this analysis is outlined in red. The 2 groups were compared by use of repeated measures ANOVA over time with additional corrected Bonferroni post tests at each time point (meanϮSEM percent; comparison of UPA-treated mice vs vehicle-treated mice, *PϽ0.01, **PϽ0.01, and ***PϽ0.001; nϭ3 each).
radiation-free, and portable alternative. The latter point is of pivotal importance in, for example, coronary artery thrombosis when a rapid diagnosis and therapy of myocardial infarction are of major benefit for patients.
Targeting of MBs via antibodies directed to cell adhesion molecules has been reported previously, including vascular cellular adhesion molecule-1, 19,20 intercellular adhesion molecule-1, [21] [22] [23] and P-selectin. 24 -27 Furthermore, recombinant cell adhesion proteins such as GP Ib␣ have been used successfully to target ultrasound MBs to activated von Willebrand factor on the vascular endothelium. 28 scFv have not yet been reported as targeting molecules for ultrasound MBs, and they have several advantages: ScFvs are a minimal form of a functional antibody lacking the Fc region and therefore are minimally immunogenic. 29 They are easy to modify with specific tags for detection and specific groups for bioconjugation, which avoids loss of function owing to nonspecific coupling. The cost of production in prokaryotic hosts is generally low. 29 Typically, studies in the past successfully demonstrated molecular imaging in tissues in which flow velocities are low or at sites with low wall shear stress. 30 -33 Dual targeted MBs, commonly including selectins as targets, have been proposed and tested in vitro as a means to allow targeting under higher wall shear stress. 34, 35 In our study, flow chamber adhesion assays demonstrated that LIBS-MBs on their own, as a monotargeting approach, are sufficient to bind fast and firmly to their target, the activated GP IIb/IIIa receptor. Our in vivo data provide proof of concept that our scFv-conjugated MBs are suitable for molecular imaging of arterial thrombosis under high wall shear stress and high flow velocity.
Platelet-targeted MBs can be used to monitor the success or failure of thrombolysis in ultrasound. The mechanism for this is based on either the recirculation of a sufficient number of MBs or a second injection of MBs. In the first scenario, recirculating MBs are available to stain the remaining disintegrating thrombus. In the second scenario, after a longer time period (eg, Ͼ20 minutes), when the number of recirculating MBs has dropped substantially, a second injection of MBs is needed to visualize the remaining thrombus.
Elegant pioneering studies by others demonstrated the feasibility of targeting the integrin GP IIb/IIIa. 30, 32, 33 MRX408, an arginine-glycine-aspartic acid (RGD) analog, and the non-activation-specific antibody fragment abciximab have been used in particular for this approach. 30, 32, 33 RGD analogs are ligand mimetics that bind to all circulating platelets but also to other cells on the basis of their crossreactivity toward other RGD ligand-recognizing integrins. Similarly, abciximab binds to all circulating platelets and cross-reacts with other integrin receptors. 36, 37 Furthermore, abciximab is used as a therapeutic drug, preventing platelet aggregation and thrombus formation, for example, in patients undergoing percutaneous coronary interventions. As a result of its strong affinity to the GP IIb/IIIa receptor, abciximab inhibits platelet function for several days, which comes at the cost of a potentially increased risk of bleeding. 38, 39 The scFv anti-LIBS is exclusive in its specificity for the target molecule GP IIb/IIIa, the activated conformation of this integrin receptor, and the preservation of the GP IIb/IIIa ligand binding function, thereby representing a unique targeting approach for molecular imaging. 9 -15 There are several clinical scenarios in which ultrasound molecular imaging with MBs targeted to the activated GP IIb/IIIa receptor could be useful. Following the data from the in vivo mouse model, using ultrasound molecular imaging to detect a thrombus in the carotid artery appears to be feasible, providing the ability to identify high-risk plaques and thrombi prone to dislodge and to cause strokes. This diagnostic technique might also provide us with the ability to distinguish between arterial platelet-rich thrombi and venous thrombi, which is primarily coagulatory factor driven and contains fewer platelets. Furthermore, molecular ultrasound imaging with platelet-targeted MBs allows monitoring of therapeutic thrombolysis. This could be used to detect success or failure of therapeutic interventions in thrombotic disease.
Another potential area of application that is of high clinical interest is the molecular imaging/detection of thrombi in the cardiac chambers, with a focus on the left atrial appendage. Previous data indicate that scFv anti-LIBS can be used to detect older thrombi. 15 Therefore, our scFv anti-LIBS might be suitable to detect thrombi formed over longer time periods in the left atrium, eg, during atrial fibrillation. However, the influence of thrombus age on scFv anti-LIBS has to be systematically evaluated further.
Limitations
The Vevo770 small-animal ultrasound system that we used incorporates linear contrast agent imaging software, whereas clinical scanners typically use nonlinear software. However, a clinical scanner is not tailored for imaging of small vessels such as the carotid artery of mice because of the requirement of high-frequency transducers. Our experiments with the clinical scanner iE33 and the use of phantoms can provide only an indication that results from the proof-of-concept studies in mice are transferrable to the clinical setting ( Figure  VIII in the online-only Data Supplement). Ultimately, the suitability of our novel approach of targeted molecular imaging of thrombi remains to be tested and proven in humans. In addition, it should be highlighted that the MB dose used in mice was quite large and, despite this, the signal intensity at the clot was only modest. The relation between MB dose and signal intensity also will ultimately have to be established in patients. However, the potential of our targeting approach to provide enrichment of MBs at the clot may be of particular benefit in this regard.
MB destruction via ultrasound scanning might be of concern. We imaged at a frame rate of 12 Hz and used a transducer with a low mechanical index of 0.14. With these settings, an extensive destruction of MBs would not be expected. 40 If MB destruction occurred, it happened at a level that did not prevent contrast-enhanced ultrasound imaging in our in vivo experiments.
The use of the biotin/streptavidin binding for scFv coupling offers major advantages such as flexibility and rapid coupling. However, although biotinylated drugs and avidinbased reagents have been introduced in the clinic recently, potential problems with immunogenicity may limit their use in humans. 41, 42 Therefore, we are currently developing novel enzymatic bioconjugation techniques that can be adapted for use with our ultrasound molecular imaging approach. 43 One such approach for bioconjugation is the use of the Staphylococcus aureus enzyme sortase A for coupling of scFvs to sulfhydryl functionalized MBs. This provides highly functional MBs, as shown in flow chamber adhesion assays ( Figure IX in the online-only Data Supplement).
Perspective
In this study, we chose to target MBs to the activated GP IIb/IIIa receptor, which is an ideal target that is highly abundant and uniquely cell specific. Platelets are major players throughout the development of atherosclerosis, particularly in the final stage of plaque rupture resulting in arterial thrombosis. 1,6,44 -47 Atherothrombosis is the major cause of acute myocardial infarction and sudden death, yet definitive detection of the rupture-prone, vulnerable plaques is typically made only postmortem. These pathological studies have shown that thrombi containing activated platelets exist long before the presentation of sudden coronary death, indicating that vessel occlusion is often preceded by (micro) rupture associated with nonocclusive events. 48 Our method of diagnostic ultrasound imaging with LIBS-MBs might offer the sensitivity and specificity to identify those microthrombi before rupture. Furthermore, given the ability to specifically target thrombi, antithrombotic or fibrinolytic drugs could be incorporated into the MBs. Ultrasound bursts can be used to destroy the MBs and thus release the drug load locally at the thrombus.
Conclusions
Our study indicates that LIBS-MBs bind specifically to activated platelets in vitro and in vivo, thereby facilitating ultrasound molecular imaging of thrombi. Thrombus size and a reduction in thrombus size after pharmacological fibrinolysis can be monitored in real time, offering early diagnosis and monitoring of therapeutic thrombolysis. This proof-ofconcept study justifies further development toward ultrasound diagnosis of thrombotic disease and monitoring of thrombolytic therapy in humans. To achieve this, further preclinical testing, including characterization of targeting of thrombi in different vessel areas and optimization of biocompatible conjugation strategies, is the next step toward transition into clinical application.
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